MEDP
NEUTRAL
$501.23
Live
Medpace Holdings, Inc. · NASDAQ
Target $500.08
(-0.2%)
$250.05
52W Range
$628.92
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$14.31B
P/E
32.76
ROE
70.2%
Profit margin
17.8%
Debt/Equity
0.3
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Medpace exhibits strong operational health with a Piotroski F-Score of 7/9 and an exceptional ROE of 70.23%, reflecting a high-efficiency growth engine. However, the stock is significantly overvalued from a defensive standpoint, trading at $501.23 against a Graham Number of $74.63 and slightly above its growth-based intrinsic value of $451.35. While revenue and earnings growth remain robust, the high PEG ratio (2.98) and aggressive insider selling by the CEO and President suggest the current price may have peaked. The overall profile is that of a high-quality company trading at a premium valuation.
Key Strengths
Exceptional Return on Equity (ROE) of 70.23%
Strong Piotroski F-Score (7/9) indicating financial strength
Consistent earnings beat track record over 25 quarters
Robust top-line growth with 32% YoY revenue increase
High gross margins (71.06%) providing significant pricing power
Key Risks
Extreme valuation premium (Price/Book of 30.98)
Liquidity concerns indicated by a Current Ratio of 0.74
Heavy insider selling totaling $140.17M in the last 6 months
High PEG ratio (2.98) suggesting price is outstripping growth
Price is currently trading above the growth-based intrinsic value
AI Fair Value Estimate
Based on comprehensive analysis
$451.35
-10.0% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
56
Moderate
30
85
95
70
0
AI Verdict
High-Quality Overvalued Growth
Key drivers: Operational efficiency, Consistent EPS growth, Valuation disconnect, Insider bearishness
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E (26.07) is lower than current P/E
Watchpoints
- P/B ratio of 30.98 is extreme
- Price far exceeds Graham Number ($74.63)
- PEG ratio of 2.98 indicates overvaluation
Future
85/100
Ref Growth rates
Positives
- 32% YoY Revenue growth
- 26.9% YoY Earnings growth
- Strong Q/Q momentum
Watchpoints
- Growth must remain aggressive to justify current multiples
Past
95/100
Ref Historical trends
Positives
- Consistent earnings beats over 25 quarters
- Strong 5-year price appreciation (+181.9%)
- Steady EPS progression
Watchpoints
No urgent risks highlighted.
Health
70/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 7/9
- Low Debt/Equity ratio (0.30)
Watchpoints
- Current Ratio (0.74) and Quick Ratio (0.69) are below 1.0
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$501.23
Analyst Target
$500.08
Upside/Downside
-0.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MEDP and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings, Inc.
Primary
|
+181.9% | +160.9% | +64.2% | -5.0% | +11.3% | +1.1% |
|
ASND
Ascendis Pharma A/S
Peer
|
+53.7% | +106.6% | +48.4% | +15.5% | +2.0% | -6.1% |
|
BBIO
BridgeBio Pharma, Inc.
Peer
|
+18.4% | +720.5% | +110.0% | +68.2% | +1.8% | +2.1% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+34.2% | +30.1% | +19.1% | -6.2% | -0.5% | +3.0% |
|
IONS
Ionis Pharmaceuticals, Inc.
Peer
|
+83.9% | +101.9% | +181.4% | +7.4% | +0.5% | +0.5% |
MED
Medpace Holdings, Inc.
Primary
5Y
+181.9%
3Y
+160.9%
1Y
+64.2%
6M
-5.0%
1M
+11.3%
1W
+1.1%
ASN
Ascendis Pharma A/S
Peer
5Y
+53.7%
3Y
+106.6%
1Y
+48.4%
6M
+15.5%
1M
+2.0%
1W
-6.1%
BBI
BridgeBio Pharma, Inc.
Peer
5Y
+18.4%
3Y
+720.5%
1Y
+110.0%
6M
+68.2%
1M
+1.8%
1W
+2.1%
NBI
Neurocrine Biosciences, Inc.
Peer
5Y
+34.2%
3Y
+30.1%
1Y
+19.1%
6M
-6.2%
1M
-0.5%
1W
+3.0%
ION
Ionis Pharmaceuticals, Inc.
Peer
5Y
+83.9%
3Y
+101.9%
1Y
+181.4%
6M
+7.4%
1M
+0.5%
1W
+0.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
32.76
Forward P/E
26.07
PEG Ratio
2.98
P/B Ratio
30.98
P/S Ratio
5.66
EV/Revenue
5.48
EV/EBITDA
24.62
Market Cap
$14.31B
Profitability
Profit margins and return metrics
Profit Margin
17.83%
Operating Margin
21.63%
Gross Margin
71.06%
ROE
70.23%
ROA
16.4%
Growth
Revenue and earnings growth rates
Revenue Growth
+32.0%
Earnings Growth
+26.9%
Q/Q Revenue Growth
+32.03%
Q/Q Earnings Growth
+15.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.3
Low debt
Current Ratio
0.74
Weak
Quick Ratio
0.69
Poor
Cash/Share
$17.51
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.7B
Gross Margin
29.0%
Op. Margin
21.6%
Net Margin
19.1%
Total Assets
$2.0B
Liabilities
$1.5B
Equity
$0.5B
Debt/Equity
3.30x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-22
$N/A
2026-02-09
$4.67
+10.5% surprise
2025-10-22
$3.86
+8.1% surprise
2025-07-21
$3.1
+3.5% surprise
Healthcare Sector Comparison
Comparing MEDP against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
P/E Ratio
32.76
This Stock
vs
88.11
Sector Avg
-62.8%
(Discount)
Return on Equity (ROE)
70.23%
This Stock
vs
-86.0%
Sector Avg
-181.7%
(Below Avg)
Profit Margin
17.83%
This Stock
vs
-11.76%
Sector Avg
-251.6%
(Weaker)
Debt to Equity
0.3
This Stock
vs
3.51
Sector Avg
-91.5%
(Less Debt)
Revenue Growth
32.0%
This Stock
vs
90.15%
Sector Avg
-64.5%
(Slower)
Current Ratio
0.74
This Stock
vs
3.67
Sector Avg
-79.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MEDP
Medpace Holdings, Inc.
|
NEUTRAL | $14.31B | 32.76 | 70.2% | 17.8% | $501.23 | |
|
ASND
Ascendis Pharma A/S
|
BULLISH | $13.87B | - | -% | -31.7% | $225.98 | Compare |
|
BBIO
BridgeBio Pharma, Inc.
|
BEARISH | $14.92B | - | -% | -225.3% | $77.87 | Compare |
|
NBIX
Neurocrine Biosciences, Inc.
|
BULLISH | $13.22B | 28.15 | 16.4% | 16.7% | $131.74 | Compare |
|
IONS
Ionis Pharmaceuticals, Inc.
|
BEARISH | $12.42B | - | -70.8% | -40.4% | $75.17 | Compare |
MEDP
Medpace Holdings, Inc.
NEUTRAL
Mkt Cap
$14.3B
P/E
32.8
ROE
70.2%
Price
$501.23
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | KRAFT ROBERT O | Director | Stock Award | 33 | - |
| 2026-03-31 | CARLEY BRIAN T | Director | Stock Award | 36 | - |
| 2026-03-31 | MCCARTHY CORNELIUS P. III | Director | Stock Award | 29 | - |
| 2026-03-18 | BURWIG SUSAN ELIZABETH | Officer | Option Exercise | 12,000 | $2,000,760 |
| 2026-03-17 | GEIGER JESSE J | President | Sale | 31,707 | $14,436,197 |
| 2026-03-17 | GEIGER JESSE J | President | Option Exercise | 31,707 | $4,403,151 |
| 2026-02-17 | EWALD STEPHEN P | General Counsel | Option Exercise | 3,500 | $486,045 |
| 2026-02-13 | CARLEY BRIAN T | Director | Option Exercise | 6,472 | $355,895 |
| 2026-02-13 | BURWIG SUSAN ELIZABETH | Officer | Option Exercise | 10,984 | $1,185,503 |
| 2025-12-31 | KRAFT ROBERT O | Director | Stock Award | 56 | - |
| 2025-12-31 | CARLEY BRIAN T | Director | Stock Award | 62 | - |
| 2025-12-31 | MCCARTHY CORNELIUS P. III | Director | Stock Award | 49 | - |
| 2025-12-05 | BURWIG SUSAN ELIZABETH | Officer | Option Exercise | 10,000 | $1,079,300 |
| 2025-12-03 | TROENDLE AUGUST J | Chief Executive Officer | Sale | 668 | $394,581 |
| 2025-12-02 | TROENDLE AUGUST J | Chief Executive Officer | Sale | 28,876 | $17,114,847 |
KRAFT ROBERT O
Director
2026-03-31
33 shares
CARLEY BRIAN T
Director
2026-03-31
36 shares
MCCARTHY CORNELIUS P. III
Director
2026-03-31
29 shares
BURWIG SUSAN ELIZABETH
Officer
2026-03-18
12,000 shares
·
$2,000,760
GEIGER JESSE J
President
2026-03-17
31,707 shares
·
$14,436,197
GEIGER JESSE J
President
2026-03-17
31,707 shares
·
$4,403,151
EWALD STEPHEN P
General Counsel
2026-02-17
3,500 shares
·
$486,045
CARLEY BRIAN T
Director
2026-02-13
6,472 shares
·
$355,895
BURWIG SUSAN ELIZABETH
Officer
2026-02-13
10,984 shares
·
$1,185,503
KRAFT ROBERT O
Director
2025-12-31
56 shares
CARLEY BRIAN T
Director
2025-12-31
62 shares
MCCARTHY CORNELIUS P. III
Director
2025-12-31
49 shares
BURWIG SUSAN ELIZABETH
Officer
2025-12-05
10,000 shares
·
$1,079,300
TROENDLE AUGUST J
Chief Executive Officer
2025-12-03
668 shares
·
$394,581
TROENDLE AUGUST J
Chief Executive Officer
2025-12-02
28,876 shares
·
$17,114,847
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
12 analysts
Barclays
2026-03-06
Underweight
Equal-Weight
RBC Capital
2026-03-03
Outperform
TD Cowen
2026-02-18
Sell
Hold
Jefferies
2026-02-13
Hold
Buy
Barclays
2026-02-11
Underweight
Underweight
Truist Securities
2026-02-11
Hold
Hold
Leerink Partners
2026-02-11
Market Perform
Market Perform
Barclays
2025-12-15
Underweight
Underweight
BMO Capital
2025-11-13
Market Perform
Truist Securities
2025-10-27
Hold
Hold
Past News Coverage
Recent headlines mentioning MEDP from our newsroom.
Newest → oldest
No matching news yet.